Cytodyn Inc (CYDY)

[ClosetInvestor]

We didn't know the AVXL data; we know what CYDY is presenting: Pro 140 works as a monotherapy. Not much new besides the PK/PD data which doesn't make a big difference because Pro 140 has touted that Pro 140 works so the PK/PD HAS to be good. The hype behind the ASM is for publicity. CYDY thinks this is their chance to get their name out there and get some attention. Let's hope that's the fact.